<code id='82DC2228C1'></code><style id='82DC2228C1'></style>
    • <acronym id='82DC2228C1'></acronym>
      <center id='82DC2228C1'><center id='82DC2228C1'><tfoot id='82DC2228C1'></tfoot></center><abbr id='82DC2228C1'><dir id='82DC2228C1'><tfoot id='82DC2228C1'></tfoot><noframes id='82DC2228C1'>

    • <optgroup id='82DC2228C1'><strike id='82DC2228C1'><sup id='82DC2228C1'></sup></strike><code id='82DC2228C1'></code></optgroup>
        1. <b id='82DC2228C1'><label id='82DC2228C1'><select id='82DC2228C1'><dt id='82DC2228C1'><span id='82DC2228C1'></span></dt></select></label></b><u id='82DC2228C1'></u>
          <i id='82DC2228C1'><strike id='82DC2228C1'><tt id='82DC2228C1'><pre id='82DC2228C1'></pre></tt></strike></i>

          Home / Wikipedia / comprehensive

          comprehensive


          comprehensive

          author:focus    Page View:681
          A phone screen shows a logo of Centers for Medicare and Medicaid Services – politics coverage from STAT
          Adobe

          The federal government inappropriately lowered the 2024 Medicare Advantage star ratings of SCAN Health Plan, which led to the health insurance company in California losing hundreds of millions of dollars in bonuses from the government, a judge ruled Monday.

          The decision will lead to more than $250 million funneling back into SCAN, which covers 270,000 Medicare Advantage enrollees. And it opens the door for other Medicare Advantage plans to potentially recoup huge sums of taxpayer-funded bonuses — even though many independent experts believe the quality rating system is flawed and doesn’t appropriately gauge quality of care for older adults and people with disabilities.

          advertisement

          The Centers for Medicare and Medicaid Services, the federal agency that oversees all Medicare programs, said it does not comment on litigation. In an interview, SCAN CEO Sachin Jain told STAT that if the company had not gotten its expected bonus money, it would have had to shave benefits and reduce what it pays hospitals and doctors.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In